![Frontiers | Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer Frontiers | Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer](https://www.frontiersin.org/files/Articles/97487/fonc-04-00256-HTML/image_m/fonc-04-00256-g001.jpg)
Frontiers | Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
![Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ... Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ...](https://www.thelancet.com/cms/attachment/3fdd6731-2603-4814-8039-9bb9fa5cf394/gr1.gif)
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label ...
ecancer on Twitter: "#Chemotherapy is often the first line treatment for metastatic #breastcancer. However, patients with HR+ breast cancer may also respond well to endocrine therapy. Follow the decision tree to learn
![Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-022-00757-8/MediaObjects/41408_2022_757_Figa_HTML.png)
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies | PLOS ONE
Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice
![Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/attachment/65714/large/image1.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQP35HG4CYCAIE5XO%2F20230523%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20230523T203532Z&X-Amz-Expires=604800&X-Amz-SignedHeaders=host&X-Amz-Signature=c91d8d2ecc6318d80f39c909313a12c3b15e6f4d5a99cbd50874945f677ed63f)
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology
![Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis](https://rare-liver.eu/media/treatment_decisions_for_autimmune_hepatitis_aih_.jpg)
Lay Summary of the ERN RARE-LIVER Position Paper: Second-line and Third-line Therapy for Autoimmune Hepatitis
![Current Oncology | Free Full-Text | Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done Current Oncology | Free Full-Text | Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done](https://pub.mdpi-res.com/curroncol/curroncol-29-00506/article_deploy/html/images/curroncol-29-00506-g001.png?1662627856)
Current Oncology | Free Full-Text | Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done
Prospects in the management of patients with follicular lymphoma beyond first-line therapy | Haematologica
![Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough? | Journal of Urology Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough? | Journal of Urology](https://www.auajournals.org/cms/asset/85280ed4-4053-4d63-86d1-a4e3c10d73e2/gr1.jpg)
Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough? | Journal of Urology
![JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients](https://www.mdpi.com/jcm/jcm-09-00648/article_deploy/html/images/jcm-09-00648-g001.png)
JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
![Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0429/asset/images/medium/figure1.gif)
Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | Future Oncology
![Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1533002818304717-gr2.jpg)
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect
![Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets](https://www.lonsurfhcp.com/Content/img/mCRC/mcrc-patients-third-line-treatment.png)
Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets
![Third-Line Treatment for Metastatic GEJ and Gastric Cancer | LONSURF® (trifluridine and tipiracil) tablets Third-Line Treatment for Metastatic GEJ and Gastric Cancer | LONSURF® (trifluridine and tipiracil) tablets](https://www.lonsurfhcp.com/Content/img/mGEJ/gastic-cancer-patients-third-line-treatment.png)
Third-Line Treatment for Metastatic GEJ and Gastric Cancer | LONSURF® (trifluridine and tipiracil) tablets
![Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304419X20302067-gr1.jpg)
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box - ScienceDirect
![National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic](https://www.mayoclinic.org/-/media/kcms/gbs/medical-professionals/images/2021/05/18/17/16/overactive-diagram-fig1-767x535.jpg)
National patterns of filled prescriptions and third line treatment use for privately insured women with overactive bladder - Mayo Clinic
Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes | PLOS ONE
![Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group - ScienceDirect Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827820304700-gr2.jpg)